Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical ABI-1968 in Cervical High Grade Squamous Intraepithelial Lesions
NCT03697226Phase 1Completed
- Sponsor
- Antiva Biosciences
- Start
- Dec 2018
- Primary completion
- May 2020
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of abi-1968 in high-grade squamous intraepithelial lesion (HSIL) (5 arms), sponsored by Antiva Biosciences. Primary endpoint: Safety & Tolerability of ABI-1968 at 42 days. Started Dec 2018; status: completed.
02
Drugs
abi-1968
03
Conditions
high-grade squamous intraepithelial lesion (HSIL)
Beyond the preview
Go deeper on NCT03697226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03697226.